Azenta, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- John Marotta
- Full Time Employees
- 3,000
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- Address
- 200 Summit Drive Burlington MA United States of America 01803
- IPO Date
- Feb 2, 1995
- CIK
- 0000933974
- Website
- azenta.com
- Similar Companies
- Business
- Azenta, Inc. Azenta, Inc. (Nasdaq: AZTA) provides life sciences sample exploration and management solutions to pharmaceutical, biotechnology, academic, and healthcare institutions worldwide. The company offers consumables and instruments including 2D sample storage tubes and bench-top equipment from brands such as FluidX, Ziath, and 4titude; automated stores and cryogenics systems; sample storage and repository services through BioStorage Technologies; GENEWIZ multiomics and synthesis solutions encompassing next-generation sequencing, genomics, and transgene expression cassettes; sample management LIMS software like FreezerPro and Limfinity; cold chain solutions from B Medical Systems including temperature-controlled storage and transportation; and biological sample preparation from Matrical Bioscience. Azenta operates globally across North America, Europe, and Asia from its headquarters in Burlington, Massachusetts, where it was rebranded from Brooks Automation in December 2021 following a corporate restructuring that divested its semiconductor solutions group. Recent developments include a May 2025 strategic partnership with Form Bio to integrate GENEWIZ sequencing with AI-driven AAV gene therapy analysis for improved vector safety and development speed; and a November 2025 collaboration with the PRECEDE Foundation to provide biorepository storage and logistics for pancreatic cancer early detection research.
Azenta: Needs To Overcome A Few Hurdles If The Rally Is To Continue
Azenta, Inc. $AZTA Shares Sold by Bank of New York Mellon Corp
Arrowstreet Capital Limited Partnership Buys New Position in Azenta, Inc. $AZTA
Azenta, Inc. (AZTA) Q3 2026 Earnings Call Transcript
Azenta Q3 Earnings Call Highlights
Azenta Reports Third Quarter Results for Fiscal 2026, Ended June 30, 2026.
American Capital Management Inc. Acquires 274,588 Shares of Azenta, Inc. $AZTA
Azenta Announces Fiscal 2026 Third Quarter Conference Call and Webcast
Azenta Completes Sale of B Medical Systems
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Azenta, Inc. - AZTA
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Azenta, Inc. - AZTA
Azenta Inc (AZTA) Stock Up 5.4% and Still Undervalued -- GF Score: 72/100
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Azenta, Inc. - AZTA
Azenta, Inc. (AZTA) Securities Fraud Investigation - Levi & Korsinsky
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Azenta, Inc. - AZTA
Investors in Azenta, Inc. (AZTA) Warned of Potential Securities Fraud - Contact Levi & Korsinsky Today
Azenta, Inc. (AZTA) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
Securities Fraud Investigation Into Azenta, Inc. (AZTA) Continues -- Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
Securities Fraud Investigation Into Azenta, Inc. (AZTA) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
Securities Fraud Investigation Into Azenta, Inc. (AZTA) Continues -- Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm